What Has Been The Evolution of the Crohns Disease CD Treatment Market in Recent Years?
The crohns disease cd treatment market has seen considerable growth due to a variety of factors.
• The market size for treatment of Crohn's Disease (CD) has seen significant growth in the past few years. The size is expected to escalate from $11.76 billion in 2024 to $12.38 billion in 2025, exhibiting a 5.3% compound annual growth rate (CAGR). The remarkable growth observed in the historical period can be credited to the increasing occurrences of Crohn's disease, heightened consciousness about the condition, government efforts, and lifestyle changes.
What Are the Future Growth Projections for the Crohns Disease CD Treatment Market?
The crohns disease cd treatment market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market for Crohn's disease (CD) treatment is projected to experience impressive growth, to reach $15.06 billion in 2029, with a compound annual growth rate (CAGR) of 5.0%.
This growth during the forecast period can be attributed to the rising demand for combination therapies, the growing use of biologics, and increased investment in research and development for Crohn's disease treatments. Some of the major trends expected during this period include the development of biologic drugs, the creation of innovative products, the use of advanced diagnostic tools, and the adoption of biosimilars.
What Are The Core Factors Supporting Growth In The Crohns Disease CD Treatment Market?
The Crohn’s disease (CD) treatment market is set to witness accelerated growth due to the escalating prevalence of inflammatory bowel diseases. Inflammatory bowel disease (IBD) is a collection of chronic inflammatory conditions primarily impacting the gastrointestinal (GI) tract. The treatment for Crohn’s disease (CD) provides symptom relief, inflammation reduction, promotion of remission, and enhancement of overall quality of life for those affected by chronic inflammatory bowel disease. For instance, in September 2023, the United States National Library of Medicine, a medical library in the US, cited that Canada's incidence of inflammatory bowel diseases (IBD) was estimated to be at 30 per 100,000 person years in 2023, with a projected steady rise of about 0.58% annually. In 2023, Canada's IBD prevalence hit around 825 per 100,000, with predictions indicating a potential rise to 1.1% of the population by 2035. As a result, the rising incidence of inflammatory bowel diseases is a key driver of the Crohn’s disease (CD) treatment market.
Driving the Crohn's Disease (CD) Treatment Market: Increased Clinical Trials Contribute to its Expansion
What Are The Major Segments Within The Global Crohns Disease CD Treatment Market?
The crohn's disease (CD) treatment market covered in this report is segmented –
1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types
2) By Route of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores
Subsegments:
1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin
2) By Amino Salicylates: Mesalamine, Sulfasalazine
3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate
5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules
Pre-Book The Crohns Disease CD Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Crohns Disease CD Treatment Market?
Key players in the Crohn's disease (CD) treatment market are innovating by launching new technologies like IBDSENSE to maintain their market stance. For example, The IRR Chemistry Hub, an interdisciplinary hub based in Scotland, rolled out IBDSENSE in March 2023. This technology focuses on enhancing the diagnosis and monitoring of inflammatory bowel diseases using non-invasive methodologies, amongst which Crohn's disease is included. The initiative leverages fluorescence-based technology for the measurement of Granzyme B (GzmB) enzyme activity in patient biosamples. The objective of this technology is to elevate patient experiences and diversify treatment options.
Who Are the Key Players In The Crohns Disease CD Treatment Market?
Major companies operating in the crohn's disease (cd) treatment market are:
• Pfizer Inc.
• Johnson and Johnson Ltd.
• Merck and Co. Inc.
• AbbVie Inc.
• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Bausch Health Companies Inc.
• UCB S.A.
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company PLC
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Cipla Limited
• Ferring B.V.
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals LLC.
What Is The Most Dominant Region In The Crohns Disease CD Treatment Market?
North America was the largest region in the Crohn’s disease (CD) treatment market in 2024. The regions covered in Crohn's disease (CD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
